tradingkey.logo
tradingkey.logo
Search

Silexion Therapeutics Corp

SLXN
Add to Watchlist
1.800USD
-0.040-2.17%
Close 07-31 16:00ETQuotes delayed by 15 min
562.80KMarket Cap
LossP/E TTM

SLXN Income Statement

You can find the annual or quarterly income statement of Silexion Therapeutics Corp here for insights into the performance and operational efficiency of Silexion Therapeutics Corp.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
Operating expenses
66.61%2.75M
131.89%4.41M
-59.03%3.29M
64.91%2.28M
32.00%1.65M
9.95%1.90M
999.32%8.04M
-2.05%1.39M
54.70%1.25M
254.02%1.73M
208.44%731.00K
800.67%1.41M
130.70%808.00K
--488.11K
--237.00K
--156.99K
--350.24K
R&D expenses
132.20%1.37M
287.49%3.38M
-32.95%2.16M
32.90%1.02M
-38.61%590.00K
-30.71%871.00K
501.31%3.22M
-37.98%766.00K
41.12%961.00K
--1.26M
--535.00K
--1.23M
--681.00K
----
----
----
----
Depreciation, depletion, and amortization
-50.00%2.00K
--3.00K
-81.82%4.00K
-57.14%3.00K
-50.00%4.00K
----
120.00%22.00K
-50.00%7.00K
-46.67%8.00K
--6.00K
--10.00K
--14.00K
--15.00K
--0.00
--0.00
--0.00
--0.00
Other operating expenses
----
----
----
----
----
---13.00K
----
----
----
----
----
----
----
----
----
----
----
Operating profit
-66.61%-2.75M
-131.89%-4.41M
59.03%-3.29M
-64.91%-2.28M
-32.00%-1.65M
-9.95%-1.90M
-999.32%-8.04M
2.05%-1.39M
-54.70%-1.25M
-254.02%-1.73M
-208.44%-731.00K
-800.67%-1.41M
-130.70%-808.00K
---488.11K
---237.00K
---156.99K
---350.24K
Net non-operating interest income (expenses)
Non-operating interest income
----
--142.00K
----
----
----
----
-100.00%0.00
-84.62%6.00K
-51.28%19.00K
-96.68%33.00K
-91.92%42.00K
-76.12%39.00K
315.51%39.00K
--992.92K
--520.02K
--163.34K
--9.39K
Non-operating interest expense
----
204.17%73.00K
----
----
----
--24.00K
----
----
----
----
----
----
----
----
----
----
----
Gains from sale of securities
-1133.33%-31.00K
13.21%-46.00K
65.05%-36.00K
-38.64%-61.00K
102.83%3.00K
-148.18%-53.00K
9.65%-103.00K
91.08%-44.00K
-402.86%-106.00K
--110.00K
---114.00K
---493.00K
--35.00K
----
----
----
----
Special income (expenses)
118.99%15.00K
-112.55%-29.00K
100.73%27.00K
-209.38%-198.00K
2.47%-79.00K
359.55%231.00K
---3.72M
-3300.00%-64.00K
-8200.00%-81.00K
-756.35%-89.00K
-100.00%0.00
-94.50%2.00K
-98.95%1.00K
---10.39K
--9.56K
--36.35K
--95.19K
Income before tax
-57.52%-2.73M
-152.69%-4.41M
72.49%-3.26M
-68.12%-2.50M
-22.36%-1.73M
-4.30%-1.75M
-1376.71%-11.86M
20.31%-1.49M
-93.45%-1.42M
-438.58%-1.67M
-374.46%-803.00K
-4470.74%-1.87M
-198.38%-733.00K
--494.41K
--292.58K
--42.69K
---245.66K
Income tax
--0.00
-100.00%0.00
-100.00%0.00
50.00%3.00K
-100.00%0.00
-83.33%1.00K
-66.67%2.00K
-80.00%2.00K
-50.00%5.00K
--6.00K
--6.00K
--10.00K
--10.00K
----
----
----
----
Income after tax
-57.52%-2.73M
-152.55%-4.41M
72.50%-3.26M
-68.10%-2.50M
-21.93%-1.73M
-3.99%-1.75M
-1366.01%-11.86M
20.63%-1.49M
-91.52%-1.42M
-439.80%-1.68M
-376.51%-809.00K
-4494.16%-1.88M
-202.45%-743.00K
--494.41K
--292.58K
--42.69K
---245.66K
Net income from continuous operations
-57.52%-2.73M
-152.55%-4.41M
72.50%-3.26M
-68.10%-2.50M
-21.93%-1.73M
-3.99%-1.75M
-1366.01%-11.86M
20.63%-1.49M
-91.52%-1.42M
-439.80%-1.68M
-376.51%-809.00K
-4494.16%-1.88M
-202.45%-743.00K
--494.41K
--292.58K
--42.69K
---245.66K
Other net gains and losses
----
----
----
----
----
----
--4.00K
----
----
----
----
----
----
----
----
----
----
Net Income attributable to non-controlling interests
----
--0.00
-100.00%0.00
--0.00
----
----
--9.00K
----
----
----
----
----
----
----
----
----
----
Net income attributable to controlling interests
-57.52%-2.73M
-152.55%-4.41M
72.50%-3.26M
-68.10%-2.50M
-21.93%-1.73M
-3.99%-1.75M
-1366.01%-11.86M
20.63%-1.49M
-91.52%-1.42M
-439.80%-1.68M
-376.51%-809.00K
-4494.16%-1.88M
-202.45%-743.00K
--494.41K
--292.58K
--42.69K
---245.66K
Net income attributable to common shareholders
-57.52%-2.73M
-152.55%-4.41M
72.50%-3.26M
-68.10%-2.50M
-21.93%-1.73M
-3.99%-1.75M
-1366.01%-11.86M
20.63%-1.49M
-91.52%-1.42M
-439.80%-1.68M
-376.51%-809.00K
-4494.16%-1.88M
-202.45%-743.00K
--494.41K
--292.58K
--42.69K
---245.66K
Basic earnings per share
-3205.71%-8.46
-48.39%-1.40
69.84%-2.88
-214.83%-4.32
80.48%-0.26
38.95%-0.94
-1180.87%-9.55
20.63%-1.37
-91.52%-1.31
-5001.27%-1.55
-3883.65%-0.75
-60324.74%-1.73
-4038.69%-0.68
--0.03
--0.02
--0.00
---0.02
Diluted earnings per share
-3205.71%-8.46
-48.39%-1.40
69.84%-2.88
-214.83%-4.32
80.48%-0.26
38.95%-0.94
-1180.87%-9.55
20.63%-1.37
-91.52%-1.31
-5001.27%-1.55
-3883.65%-0.75
-60324.74%-1.73
-4038.69%-0.68
--0.03
--0.02
--0.00
---0.02
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Silexion Therapeutics Corp's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing SLXN stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Silexion Therapeutics Corp's net income for the year?

Silexion Therapeutics Corp posted -11.91M in net income for fiscal year 2025.

How much net income did Silexion Therapeutics Corp post in the last quarter?

Silexion Therapeutics Corp reported -2.73M in net income for the latest quarter。

What was Silexion Therapeutics Corp's annual operating profit?

Silexion Therapeutics Corp's operating income was -11.63M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.